Constellation Alpha

ARCHIVE OF CONSTELLATION ALPHA CAPITAL/DMTK PRESS RELEASES

PIPE

Mar 2, 2020: DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that it has entered into a definitive securities purchase agreement with certain institutional investors, which is expected to result in gross proceeds to DermTech of approximately $65.0 million.

Medicare Coverage

Jan 8, 2020: DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that the Medicare Administrative Contractor Palmetto GBA MolDx (“Palmetto”) has issued a final local coverage determination for the Pigmented Lesion Assay (“PLA”). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more clinical or historical characteristics suggestive of melanoma.

Transaction Closing

Aug 29, 2019: Constellation Alpha Capital Corp. (“Constellation”), a publicly-traded special purpose acquisition company, and DermTech, Inc. (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that they have completed their previously announced business combination. The business combination was approved by Constellation’s stockholders on August 27, 2019 with more than 90% of the voted shares in favor of the business combination.

Definitive Agreement

May 29, 2019: Constellation Alpha Capital Corp. (“Constellation”), a special purpose acquisition company, announced that it has executed a definitive agreement to merge with DermTech, Inc. (“DermTech”), a molecular genomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests.

Indicative Termsheet

Mar 15, 2019: Constellation Alpha Capital Corp. (“Constellation”), a special purpose acquisition company, announced that it has executed a non-binding Letter of Intent to merge with DermTech, Inc. (“DermTech”), a molecular genomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests.

Initial Public Offering

Jun 23, 2017: Constellation Alpha Capital Corp. (the “Company”) announced today the closing of its initial public offering of 14,375,000 units, including 1,875,000 units issued upon exercise of the underwriters’ over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $143,750,000.